Alkermes plc

Alkermes plc
Company typePublic
IndustryBiotechnology
Founded1987 (1987)
FounderMichael Wall
Headquarters
Dublin
,
Ireland[1]
Key people
Richard Pops (CEO)
Revenue US$1.47 billion (2025)[2]
US$241.7 million
US$241.7 million (2026)
Total assets US$2.4 billion
Total equity US$1.8 billion
Number of employees
2,100
Websitewww.alkermes.com

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.[3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.[1]

Products

Alkermes has five proprietary commercial drug products[5] approved for the treatment of narcolepsy, schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include sodium oxybate for extendend release oral suspension (Lumryz) olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.[6][7]

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia.[8]

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.[9]

In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk. [10]

In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia. [11]

In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1. [12]

In November 2025, Alkermes agreed to acquire sleep disorder drugmaker Avadel Pharmaceuticals for up to $2.37 billion, which includes $21 per share in cash plus $1.50 per share contingent on expanded approval of Lumryz by the end of 2028. This resulted after a bidding war between Alkermes and Danish pharmaceutical company Lundbeck. Alkermes had originally offered up to $2.1 billion, which included $18.50 per share plus the contingent $1.50. The deal closed in the first quarter of 2026.[13]

In February 2026, CEO Richard Pops announced plans to effective August 2026. His planned replacement is Blair Jackson, Alkermes' current Chief Operating Officer. [14]

Alkermes has multiple orexin 2 receptor agonists in development for the potential treatment of fatigue associated with multiple sclerosis and Parkinson's disease as well as attention-deficit hyperactivity disorder. [15]

References

  1. ^ a b Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
  2. ^ https://investor.alkermes.com/static-files/5f9eb70d-a7bd-42a7-8617-42c30f63e5b4. {{cite web}}: Missing or empty |title= (help)
  3. ^ "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
  4. ^ "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.
  5. ^ "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.
  6. ^ "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  7. ^ "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  8. ^ "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.
  9. ^ "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.
  10. ^ "Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk". alkermes.com. 2024-05-02. Retrieved 2024-06-24.
  11. ^ "Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia". Alkermes plc. April 1, 2025. Retrieved April 15, 2025.
  12. ^ "Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1a". Alkermes plc. July 21, 2025. Retrieved July 30, 2025.
  13. ^ "Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market". Alkermes. February 12, 2026. Retrieved March 17, 2026.{{cite web}}: CS1 maint: url-status (link)
  14. ^ "Alkermes plc Announces CEO Succession Plan". Alkermes. February 25, 2026. Retrieved March 17, 2026.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "Pipeline | Alkermes". www.alkermes.com. Retrieved 2026-03-17.
  • Official website
  • Business data for Alkermes plc:
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.